Key result
A peptide nucleic acid-neamine conjugate targeting HIV-1 TAR RNA demonstrated cellular uptake, specific RNA cleavage, and potent inhibition of HIV-1 replication.
Answers are grounded in this paper and cite their sources.
A novel PNA-neamine conjugate demonstrates potent inhibition of HIV-1 replication and specific RNA cleavage, suggesting potential therapeutic applications.
The neamine part of the aminoglycoside antibiotic neomycin B was conjugated to a 16 mer peptide nucleic acid (PNA) targeting HIV-1 TAR RNA. Attachment of the neamine core allows cellular uptake of the PNA and results in potent inhibition of HIV-1 replication. The polycationic neamine moiety imparts greater solubility to the PNA and also confers a unique RNA cleavage property to the conjugate which is specific to its target site and functional at physiological concentrations of Mg(2+). These properties suggest a potential therapeutic application for this class of compounds.
No takes yet. Share an insight, caveat, or question.
Riguet et al. (2004) studied HIV-1. Peptide nucleic acid-neamine conjugate was evaluated on HIV-1 replication inhibition and RNA cleavage. A peptide nucleic acid-neamine conjugate targeting HIV-1 TAR RNA demonstrated cellular uptake, specific RNA cleavage, and potent inhibition of HIV-1 replication.
Synapse has enriched 10 related papers. Consider them for comparative context: